Difference between revisions of "Drug index"
Jump to navigation
Jump to search
m (added medications) |
m (cleaned up 2011 FDA approvals) |
||
| Line 31: | Line 31: | ||
*[[Arsenic trioxide (Trisenox)]] | *[[Arsenic trioxide (Trisenox)]] | ||
*[[Asparaginase (Elspar)]] | *[[Asparaginase (Elspar)]] | ||
| − | *[[Asparaginase Erwinia chrysanthemi (Erwinaze)]] | + | *[[Asparaginase Erwinia chrysanthemi (Erwinaze)]] |
*[[Aspirin]] | *[[Aspirin]] | ||
*[[Atovaquone (Mepron)]] | *[[Atovaquone (Mepron)]] | ||
| Line 50: | Line 50: | ||
*[[Bortezomib (Velcade)]] | *[[Bortezomib (Velcade)]] | ||
*[[Bosutinib (Bosulif)]] '''FDA approved 9/4/2012''' | *[[Bosutinib (Bosulif)]] '''FDA approved 9/4/2012''' | ||
| − | *[[Brentuximab vedotin (Adcetris)]] | + | *[[Brentuximab vedotin (Adcetris)]] |
*[[Brivanib (BMS-582664)]] '''in clinical trials''' | *[[Brivanib (BMS-582664)]] '''in clinical trials''' | ||
*[[Busulfan (Myleran)]] | *[[Busulfan (Myleran)]] | ||
| Line 94: | Line 94: | ||
*[[Decitabine (Dacogen)]] | *[[Decitabine (Dacogen)]] | ||
*[[Deferasirox (Exjade)]] | *[[Deferasirox (Exjade)]] | ||
| − | *[[Deferiprone (Ferriprox)]] | + | *[[Deferiprone (Ferriprox)]] |
*[[Deferoxamine (Desferal)]] | *[[Deferoxamine (Desferal)]] | ||
*[[Degarelix (Firmagon)]] | *[[Degarelix (Firmagon)]] | ||
| Line 156: | Line 156: | ||
==H== | ==H== | ||
| − | *[[Hematopoetic progenitor cells, cord blood (Hemacord)]] | + | *[[Hematopoetic progenitor cells, cord blood (Hemacord)]] |
*[[Heparin]] | *[[Heparin]] | ||
*[[HER2 peptide vaccine (AE37)]] '''in clinical trials''' | *[[HER2 peptide vaccine (AE37)]] '''in clinical trials''' | ||
| Line 256: | Line 256: | ||
*[[Ridaforolimus (AP23573)]] '''in clinical trials''' | *[[Ridaforolimus (AP23573)]] '''in clinical trials''' | ||
*[[Rituximab (Rituxan)]] | *[[Rituximab (Rituxan)]] | ||
| − | *[[Rivaroxaban (Xarelto)]] | + | *[[Rivaroxaban (Xarelto)]] |
*[[Romidepsin (Istodax)]] | *[[Romidepsin (Istodax)]] | ||
*[[Romiplostim (Nplate)]] | *[[Romiplostim (Nplate)]] | ||
| − | *[[Ruxolitinib (Jakafi)]] | + | *[[Ruxolitinib (Jakafi)]] |
==S== | ==S== | ||
| Line 290: | Line 290: | ||
*[[Tositumomab & I-131 (Bexxar)]] | *[[Tositumomab & I-131 (Bexxar)]] | ||
*[[Trabectedin (Yondelis)]] | *[[Trabectedin (Yondelis)]] | ||
| − | *[[Trametinib (GSK1120212, JTP-74057)]] | + | *[[Trametinib (GSK1120212, JTP-74057)]] '''in clinical trials''' |
*[[Trastuzumab (Herceptin)]] | *[[Trastuzumab (Herceptin)]] | ||
*[[Trastuzumab emtansine (T-DM1)]] '''in clinical trials''' | *[[Trastuzumab emtansine (T-DM1)]] '''in clinical trials''' | ||
| Line 305: | Line 305: | ||
*[[Veliparib (ABT-888)]] '''in clinical trials''' | *[[Veliparib (ABT-888)]] '''in clinical trials''' | ||
*[[Veltuzumab (hA20)]] '''in clinical trials''' | *[[Veltuzumab (hA20)]] '''in clinical trials''' | ||
| − | *[[Vemurafenib (Zelboraf)]] | + | *[[Vemurafenib (Zelboraf)]] |
*[[Vinblastine (Velban)]] | *[[Vinblastine (Velban)]] | ||
*[[Vincristine (Oncovin)]] | *[[Vincristine (Oncovin)]] | ||
Revision as of 18:55, 17 January 2013
- Antidepressants and other psychiatric medications in cancer care
- Antiemetic support
- Antimicrobial Prophylaxis and Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: American Society of Clinical Oncology Clinical Practice Guideline (2013)
- Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline[1]
- ASCO-ONS Standards for Safe Chemotherapy Administration (2011)
- Chemotherapy Administration Sequence[2] - with chemotherapy sequencing chart
- FDA drug shortages list
- Steroid conversions
- Vesicant & irritant chemotherapy
A
- Abiraterone (Zytiga)
- Afatinib (BIBW 2992) in clinical trials
- Aldesleukin (Proleukin)
- Alemtuzumab (Campath)
- All-trans retinoic acid (ATRA)
- Altretamine (Hexalen)
- Amatuximab (MORAb-009) in clinical trials
- AMG 386 in clinical trials
- Amifostine (Ethyol)
- Aminocaproic acid (Amicar)
- Aminoglutethimide (Cytadren)
- Amrubicin (Calsed)
- Amsacrine (Amsidine)
- Anagrelide (Agrylin)
- Anastrozole (Arimidex)
- Antithrombin III (human and recombinant)
- Antithymocyte globulin (ATG)
- Apixaban (Eliquis) FDA approved 12/28/2012
- Argatroban
- Arsenic trioxide (Trisenox)
- Asparaginase (Elspar)
- Asparaginase Erwinia chrysanthemi (Erwinaze)
- Aspirin
- Atovaquone (Mepron)
- Axitinib (Inlyta) FDA approved 1/27/2012
- Azacitidine (Vidaza)
B
- Bacillus Calmette-Guerin (BCG)
- Bendamustine (Treanda)
- Bevacizumab (Avastin)
- Bexarotene (Targretin)
- Bicalutamide (Casodex)
- Bivalirudin (Angiomax)
- BHQ880 (Anti-DKK1 Antibody) in clinical trials
- BKM120 in clinical trials
- Bleomycin (Blenoxane)
- Blinatumomab (MT103) in clinical trials
- Bortezomib (Velcade)
- Bosutinib (Bosulif) FDA approved 9/4/2012
- Brentuximab vedotin (Adcetris)
- Brivanib (BMS-582664) in clinical trials
- Busulfan (Myleran)
C
- Cabazitaxel (Jevtana)
- Cabozantinib (Cometriq) FDA approved 11/29/2012
- CAL-101 in clinical trials
- Calcium phosphate rinse (Caphosol)
- Capecitabine (Xeloda)
- Carboplatin (Paraplatin)
- Carfilzomib (Kyprolis) FDA approved 7/20/2012
- Carmustine (BiCNU)
- Carmustine wafer, polifeprosan 20 (Gliadel)
- CAT-3888 (BL22) in clinical trials
- Catumaxomab (Removab) in US clinical trials
- Cetuximab (Erbitux)
- Chlorambucil (Leukeran)
- Cisplatin (Platinol)
- Cladribine (Leustatin)
- Clofarabine (Clolar)
- Clopidogrel (Plavix)
- Crizotinib (Xalkori)
- Cyanocobalamin (Vitamin B12)
- Cyclophosphamide (Cytoxan)
- Cyclosporine modified (Neoral)
- Cyclosporine non-modified (Sandimmune)
- Cytarabine (Cytosar)
- Cytarabine liposomal (DepoCyt)
- Cytomegalovirus (CMV) Human Immunoglobulin (Cytogam)
D
- Dabigatran (Pradaxa)
- Dabrafenib (GSK2118436)
- Dacarbazine (DTIC)
- Dacomitinib (PF-00299804) in clinical trials
- Dactinomycin (Cosmegen)
- Dalteparin (Fragmin)
- Darbepoetin alfa (Aranesp)
- Dasatinib (Sprycel)
- Daunorubicin (Cerubidine)
- Daunorubicin liposomal (DaunoXome)
- Decitabine (Dacogen)
- Deferasirox (Exjade)
- Deferiprone (Ferriprox)
- Deferoxamine (Desferal)
- Degarelix (Firmagon)
- Denileukin diftitox (Ontak)
- Denosumab (Xgeva)
- Desmopressin (DDAVP)
- Dexamethasone (Decadron)
- Dexrazoxane (Zinecard)
- DN24-02 in clinical trials
- Docetaxel (Taxotere)
- Dovitinib (TKI-258) in clinical trials
- Doxorubicin (Adriamycin)
- Doxorubicin liposomal (Doxil)
- Dutasteride (Avodart)
E
- Eculizumab (Soliris)
- Elotuzumab (HuLuc63) in clinical trials
- Eltrombopag (Promacta)
- Enoxaparin (Lovenox)
- Entinostat in clinical trials
- Enzalutamide (Xtandi) FDA approved 8/31/2012
- Epirubicin (Ellence)
- Epoetin alfa (Procrit)
- Eribulin (Halaven)
- Erlotinib (Tarceva)
- Estramustine (Emcyt)
- Etoposide (Vepesid)
- Everolimus (Afinitor)
- Exemestane (Aromasin)
F
- Factor VIIa, recombinant (NovoSeven RT)
- Factor VIII, human and recombinant (antihemophilic factor 8)
- Factor IX, human and recombinant (coagulation factor 9)
- Factor IX complex (Profilnine)
- Factor XIII concentrate, human (Corifact)
- Ferric gluconate (Ferrlecit)
- Ferrous sulfate (Feosol)
- Ferumoxytol (Feraheme)
- Fibrinogen concentrate, human (RiaSTAP)
- Filgrastim (Neupogen)
- Finasteride (Proscar)
- Fluorouracil (5-FU)
- Floxuridine (FUDR)
- Fludarabine (Fludara)
- Flutamide (Eulexin)
- Folinic acid (Leucovorin)
- Fondaparinux (Arixtra)
- Fulvestrant (Faslodex)
G
- Galeterone (TOK-001) in clinical trials
- Ganetespib (STA-9090) in clinical trials
- Ganitumab (AMG 479) in clinical trials
- Gefitinib (Iressa)
- Gemcitabine (Gemzar)
- Gemtuzumab ozogamicin (Mylotarg)
- Glucarpidase (Voraxaze) FDA approved 1/17/2012
- Goserelin (Zoladex)
H
- Hematopoetic progenitor cells, cord blood (Hemacord)
- Heparin
- HER2 peptide vaccine (AE37) in clinical trials
- Hydroxyurea (Hydrea)
I
- Ibritumomab tiuxetan (Zevalin)
- Ibrutinib (PCI-32765) in clinical trials
- Idarubicin (Idamycin)
- Ifosfamide (Ifex)
- Imatinib (Gleevec)
- Inotuzumab ozogamicin (CMC-544) in clinical trials
- Ipilimumab (Yervoy)
- Interferon alfa-2a (Roferon-A)
- Interferon alfa-2b (Intron-A)
- IPH 2101 (Anti-KIR) in clinical trials
- Irinotecan (Camptosar)
- Iron dextran (INFeD)
- Iron sucrose (Venofer)
- Ixabepilone (Ixempra)
L
- Lapatinib (Tykerb)
- Lenalidomide (Revlimid)
- Lepirudin (Refludan)
- Letrozole (Femara)
- Leuprolide (Lupron)
- Levoleucovorin (Fusilev)
- Lomustine (Ceenu)
M
- Mechlorethamine (Mustargen)
- Melphalan (Alkeran)
- Mercaptopurine (Purinethol)
- Mesna (Mesnex)
- Methotrexate (MTX)
- Methoxsalen (Uvadex)
- Mitomycin (Mutamycin)
- Mitotane (Lysodren)
- Mitoxantrone (Novantrone)
- MLN9708 (MLN2238) in clinical trials
- Motesanib (AMG 706) in clinical trials
- Moxetumomab pasudotox (HA22) in clinical trials
- Mycophenolate mofetil (CellCept)
N
- Nelarabine (Arranon)
- Neratinib (HKI-272) in clinical trials
- Nilotinib (Tasigna)
- Nilutamide (Nilandron)
- NovoTTF-100A device
O
- Obinutuzumab (GA101) in clinical trials
- Octreotide (Sandostatin)
- Odanacatib (MK-0822) in clinical trials
- Ofatumumab (Arzerra)
- Olaparib (AZD-2281) in clinical trials
- Omacetaxine (Synribo) FDA approved 10/26/2012
- Onartuzumab (MetMAb) in clinical trials
- Oxaliplatin (Eloxatin)
P
- Paclitaxel (Taxol)
- Paclitaxel, nanoparticle albumin-bound (Abraxane)
- Pamidronate (Aredia)
- Panitumumab (Vectibix)
- Panobinostat (LBH589) in clinical trials
- Pazopanib (Votrient)
- PD 991, PD0332991 in clinical trials
- Pegaspargase (Oncaspar)
- Pegfilgrastim (Neulasta)
- Peginterferon alfa-2a (Pegasys)
- Peginterferon alfa-2b (PegIntron)
- Pemetrexed (Alimta)
- Pentamidine (Nebupent)
- Pentostatin (Nipent)
- Pertuzumab (Perjeta) FDA approved 6/8/2012
- Phytonadione (Vitamin K)
- Pixantrone (BBR 2778) in clinical trials
- Plerixafor (Mozobil)
- Plicamycin (Mithracin)
- Pomalidomide (Actimid) in clinical trials
- Ponatinib (Iclusig) FDA approved 12/14/2012
- Porfimer (Photofrin)
- Pralatrexate (Folotyn)
- Prednisone (Sterapred)
- Prednisolone (Millipred)
- Procarbazine (Matulane)
- Protamine sulfate
R
- Radium-223 (Alpharadin) in clinical trials
- Raloxifene (Evista)
- Ramucirumab (IMC-1121B) in clinical trials
- Regorafenib (Stivarga) FDA approved 9/27/2012
- Reovirus (Reolysin) in clinical trials
- Retaspimycin (IPI-504) in clinical trials
- Ridaforolimus (AP23573) in clinical trials
- Rituximab (Rituxan)
- Rivaroxaban (Xarelto)
- Romidepsin (Istodax)
- Romiplostim (Nplate)
- Ruxolitinib (Jakafi)
S
- Samarium-153 (Quadramet)
- SAR3419 in clinical trials
- Sargramostim (Leukine)
- Selumetinib (AZD6244) in clinical trials
- Semuloparin (AVE5026) in clinical trials
- Sipuleucel-T (Provenge)
- Sorafenib (Nexavar)
- Streptozocin (Zanosar)
- Sunitinib (Sutent)
T
- Tacrolimus (Prograf)
- Tamoxifen (Nolvadex)
- Temozolomide (Temodar)
- Temsirolimus (Torisel)
- Teniposide (Vumon)
- Tesetaxel (DJ-927) in clinical trials
- TH-302 in clinical trials
- Thalidomide (Thalomid)
- Thioguanine (Tabloid)
- Thiotepa (Thioplex)
- Tigatuzumab (CS-1008) in clinical trials
- Tivantinib (ARQ 197) in clinical trials
- Tivozanib (AV-951) in clinical trials
- Topotecan (Hycamtin)
- Toremifene (Fareston)
- Tositumomab & I-131 (Bexxar)
- Trabectedin (Yondelis)
- Trametinib (GSK1120212, JTP-74057) in clinical trials
- Trastuzumab (Herceptin)
- Trastuzumab emtansine (T-DM1) in clinical trials
- Tretinoin (Vesanoid)
- Trimethoprim/Sulfamethoxazole (Bactrim DS)
- Triptorelin (Trelstar LA)
U
V
- Valrubicin (Valstar)
- Vandetanib (Caprelsa)
- Veliparib (ABT-888) in clinical trials
- Veltuzumab (hA20) in clinical trials
- Vemurafenib (Zelboraf)
- Vinblastine (Velban)
- Vincristine (Oncovin)
- Vincristine liposomal (Marqibo) FDA approved 8/9/2012
- Vindesine (Eldisine)
- Vinorelbine (Navelbine)
- Vismodegib (Erivedge) FDA approved 1/30/2012
- Volasertib (BI 6727) in clinical trials
- Von Willebrand Factor and factor VIII complex, human
- Vorinostat (Zolinza)
W
Z
- Ziv-aflibercept (Zaltrap) FDA approved 8/3/2012
- Zoledronic acid (Zometa)
References
- ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
- ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article